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Abstract 
To explore the spatial and temporal localization of PKC isoforms during ischemia, we quantified PKC isoforms in the subcellular 
fractions in perfused rat heart by immunoblotting using specific antibodies against PKC isoforms. PKCs-a and e translocated from the 
100000 × g supernatant (S, cytosolic) fraction to the 1000 × g pellet (P1, nucleus-myofibril) and the 1000-100000 × g pellet (P2, 
membrane) fractions during 5-40 min of ischemia. PKC-6 redistributed from the P2 to the S fraction. A 50-kDa fragment of PKC-a 
appeared uring ischemia possibly through calpain action. Immunohistochemical observations showed the different localizations of 
PKC-a, 3, and e in the myocytes. The PKC assay displayed high basal levels of CaZ+-independent PKC, the activation of 
Ca2+-dependent PKC in the PI and P2 fractions, and the activation of CaZ+-independent PKC in the P1 fraction after 20 min of ischemia. 
These observations show that ischemia induces different patterns of translocation f the three PKC isoforms, suggesting differences in 
their roles. 
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1. Introduction 
There are several lines of evidence that implicates 
protein kinase C (PKC) in various aspects of ischemic 
heart disease. For example, short ischemia results in con- 
tractile dysfunction during reperfusion, possibly as a result 
of a reduction in myofilament Ca2+-sensitivity through the 
phosphorylation f troponin [1-3]. It is also postulated that 
PKC modulates intracellular concentrations of Ca 2+, Na +, 
and H + ions through the phosphorylation of the L-type 
CaZ+-channel [4] and Na+/H+-exchanger [5,6], thereby 
regulating Ca2+-dependent contractility or modulating my- 
ocardial injury [4-7]. PKC is also known to mediate the 
protective ffect of cycle(s) of brief ischemia-reperfusion 
(ischemic preconditioning) against infarction caused by 
subsequent long ischemia [8,9]. On the other hand, many 
studies implicate PKC in responses leading to myocardial 
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hypertrophy: transactivation f early immediate genes and 
contractile protein genes, as well as enhanced protein 
synthesis following hormonal or mechanical stimuli [10,11]. 
Cells respond to hormones, ischemia, or other diverse 
stimuli by generating second messengers such as diacyl- 
glycerol, phosphatidylinositols, and cyclic nucleotides 
[12-14]. Diacylglycerol activates protein kinase C (PKC), 
which plays pivotal roles in intracellular signal transduc- 
tion [12]. PKC translocates to various cellular compart- 
ments in an activated form. This translocation may act in 
targeting PKC to specific substrates in diverse locations to 
induce relevant cellular responses at the proper time 
[12,15,16]. 
More than ten PKC isoforms have been discovered and 
categorized into Ca2+-dependent (conventional, c) PKC, 
Ca2+-independent ( ovel, n) PKC, and diacylglycerol-in- 
dependent (atypical, a) PKC isoforms [12]. In the heart, the 
presence of cPKC-ce, /3, nPKC-6, ~ and aPKC-~" has been 
reported, but the presence of PKC-a, /3, ~ remains contro- 
versial [17-24]. Although there are several reports in 
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which PKC isoforms were quantified in the subcellular 
fractions of the cardiomyocytes and hearts by immuno- 
blotting after treatment with hormones or phorbol esters 
[17-22], there are no reports on ischemia or reperfusion 
except for two reports on the translocation of PKC activity 
[14,25]. 
To investigate the functional differentiation of PKC 
isoforms during ischemia, we investigated the distribution 
of PKC isoforms during 5-40 min of ischemia in the 
perfused rat by immunoblotting and immunohistochem- 
istry using isoform specific antibodies. 
The homogenate was mixed with an equal volume of STE 
buffer and centrifuged at 1000 × g for 10 min, then the 
supernatant was centrifuged at 100000 X g for 60 min. 
The 1000 X g pellet and 100000 x g pellet were desig- 
nated as P1 and P2, respectively, while the 100000 X g 
supernatant was referred to as S. The P1 and P2 fractions 
were suspended in STE buffer. Protein concentrations were 
determined by the method of Bradford, using bovine serum 
albumin as a standard [29]. To assess the composition of 
the P1 and P2 fractions, some specimens were analyzed by 
electron microscopy. 
2. Materials and methods 
2.1. Materials 
Antibodies to PKCs- 6, E, ~ and their antigenic pep- 
tides were obtained from Gibco, the ECL Western blotting 
detection kit was from Amersham, the Vectastain ABC kit 
was from Vector Laboratories, prestaininig markers for 
PAGE were from Bio-Rad, the biotin-blocking system was 
from Dako, and the OCT compounds was from Miles, and 
the Pep Tag TM PKC assay kit was from Promega. 
2.2. Preparation of antibodies 
Antibodies to the c~-, /31- and /3II-isoforms of PKC 
were raised in rabbits injected with synthetic peptides 
(amino acids: c~, 666-672; /3I, 655-671; /3II, 663-673), 
purified by affinity chromatography, and specified as pre- 
viously reported [26]. 
2.3. Perfusion procedure 
2.5. Immunoblotting and quantitation of PKC 
The fractions were subjected to SDS-polyacrylamide 
gel electrophoresis u ing 7.5% polyacrylamide gels by the 
method of Laemmli [30], and then to immunoblotting 
according to Towbin et al. [31]. The amount of protein 
applied to the gel was varied for each isoform and fraction 
to obtain linearity with the intensity X area (volume) of the 
band on the immunoblot. The blots were blocked with 5% 
skim milk in buffer containing 150 mM NaC1, 10 mM 
Tris-HC1, pH 7.4, 0.05% Tween-20 for at least 1 h, 
incubated with one of the 2000-3000-fold iluted antibod- 
ies against PKC isoforms for 1 h at room temperature, and 
the PKC isoforms were visualized by an ECL Western 
blotting detection kit. For preadsorption experiments, the 
antibodies were preincubated with immunizing peptides 
(10 /~g/ml) for 30 min or more before application. The 
amounts of parent PKC isoforms on the immunoblots were 
measured by densitometry (Densitograph AE-6900, Atto). 
The amounts of PKC isoforms (mean _ SE) in each frac- 
tion were corrected for the variation in protein recovery. 
Male Wistar rats weighing about 200 g were anes- 
thetized with sodium pentobarbital (1 mg/ml,  i.p.) and the 
hearts were quickly excised. As previously reported [27,28], 
the hearts were perfused with Krebs-Hensleit (KH) solu- 
tion gassed with 95% 02-5% CO 2 at a constant pressure 
of 80 cm H20 for about 10 min and then rendered 
ischemic for 5-40 min at 37°C. Five rats were sacrificed 
for each condition. After ischemia, the ventricles were 
quickly separated, blotted to remove the buffer, frozen in 
liquid nitrogen and stored at -70°C for later biochemical 
analyses. 
2.4. Subcellular f actionation 
The frozen hearts were minced and homogenized in 5 
volumes of buffer containing 320 mM sucrose, 10 mM 
Tris-HC1, pH 7.4, 1 mM EGTA, 5 mM NaN 3, 10 mM 
/3-mercaptoethanol, 20 /zM leupeptin, 0.15 /zM pepstatin 
A, 0.2 mM phenylmethanesulfonyl fluoride, 50 mM NaF 
(STE buffer) with a Polytron homogenizer at the maxi- 
mum speed (PT1200, Kinematica AG) in three 15-s bursts. 
2.6. Protein kinase C assay 
The P1 and P2 fractions were treated with 0.3% Triton 
X-100 and centrifuged at 10000 × g for 10 min to obtain 
the supematant. The PKC activity was measured at 30°C 
using a PKC assay kit in 17.5 /zl of buffer containing 20 
mM Tris-HC1, pH 7.4, 10 mM MgC12, 1 mM dithio- 
threitol, 1.5 mM CaC12 (Ca2+-dependent ac ivity)or 1 mM 
EGTA (Ca2+-independent ac ivity), 1 mM ATP, 20/xg/ml  
of phosphatidylserine, 0.08 mg/ml  of specific fluorescent 
peptide for PKC (PLSRTLSVAAK), and the extract (2-5 
/zg protein). After incubation for 20 min, the specimens 
were mixed with 7.5 /~1 of 50% glycerol, and heated at 
95°C for 10 min. The samples were subjected to agarose 
(0.8%) gel electrophoresis in buffer containing 20 mM 
Tris-HC1, pH 8.0, at a constant voltage of 120 V for 25 
min to separate the phosphorylated and unphosphorylated 
substrates. The fluorescent substrates were visualized un- 
der UV light and the spots were quantified by densitom- 
etry. Specific activity, calculated from the density of the 
phosphorylated spots, was expressed in arbitrary units. 
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2.7. In vitro proteolysis 2.8. Statistical analyses 
Bovine lung m-calpain (specific activity: 40 U /mg 
protein) was partially purified by DEAE-cellulose chro- 
matography as described previously [27]. An aliquot of S 
fraction (1.5 mg/ml ) ,  isolated from control heart and 
dialyzed against STE buffer without leupeptin, was incu- 
bated with m-calpain (0.1 U /ml )  in the presence of 1.5 
mM CaC12 and 10 /xg /ml  phosphatidylserine at 37°C for 
30 min in the presence or absence of calpain inhibitor-1 
(100 /~M) and immunoblotted as described above. 
Statistical analyses were performed by ANOVA with 
posthoc analysis by the method of Fisher. 
2.9. Immunohistochemistry 
The ventricles were removed, immersed in OCT com- 
pounds, and rapidly frozen in liquid nitrogen. After sec- 
tioning at 6 /zm, the specimens were fixed on glass slides 
with 70% acetone-30% methanol ( -20°C)  for 10 min at 
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Fig. 1. Ischemia-induced translocation f PKC-o~ in myocardial subfractions a shown by representative mmunoblots (panel A) and quantitation f the 
blots (means + SE, n = 5) (panel B). The amounts of P1, P2 and S fractions applied were 30/~g, 30/.~g and 20/~g protein, respectively. PKC-~ increased 
in P1 and P2 fraction in proportion to time of ischemia, peaking at 10-20 rain, while it decreased in the S fraction with the appearance of a small amount 
of a 50 kDa band ( * P < 0.05 vs. control). The tool wt. of the standard proteins are indicated to the right. 
diaminobenzidine. Preadsorption of the antibodies was per- 
formed as described above for immunoblotting. 
4°C and washed in phosphate-buffered saline (PBS, pH 
7.3) for 10 min. Endogenous biotin was blocked by a 
biotin-blocking system. After washing with PBS and 
blocking with 1.5% normal serum in PBS, the specimens 
were incubated with one of the antibodies to PKC iso- 
forms, diluted 1000-folds, in 1% bovine serum albumin in 
PBS for one hour at room temperature and then immunos- 
tained by the avidin-biotin-peroxidase complex (ABC) 
method of Hsu et al. [32] using an ABC kit. The peroxi- 
dase label was visualized by exposing the sections to 
3. Results 
S 
We examined the localization of PKC isoforms in sub- 
cellular fractions by immunoblotting with isoform specific 
antibodies. Electron microscopic observation showed that 
the P1 fraction contained the nuclei, myofibrils, and a few 
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Fig. 2. Ischemia-induced translocation f PKC-8 in myocardial subfractions a shown by representative immunoblots (panel A) and the quantitation f the 
blots (means + SE, n = 5) (panel B). The amounts of P1, P2 and S fractions applied were 15 ~g, 15 ~g and 10 /xg protein, respectively. PKC-6 
translocated from the P2 to the S fraction in proportion to the time of ischemia ( * P < 0.05 vs. control). 
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unbroken cells, while the P2 fraction included membrane 
vesicles and the mitochondria (not shown). We previously 
showed that the P1 and P2 fractions were enriched in 
actomyosin and Na+-K+-ATPase activity, respectively [27]. 
The recoveries of histone H1 and troponin-T in the P1 
fraction were almost 100% and was not altered during 
ischemia (not shown). It is impossible to separate the 
myofibrilar PKC and nuclear PKC from the P1 fraction 
because both PKC species are extracted by the treatment 
with Triton X-100 used to isolate the myofibrils. The P1, 
P2 and S fractions contained about 70, 5 and 25% of the 
total protein, respectively, without significant changes in 
recovery during 5-40 min of ischemia (not shown). For 
the immunoblots hown in Figs. 1-3 (panels A), equal 
amounts of protein for each fraction (indicated in the 
figure legends) were applied; the amount of PKC isoform 
in a fraction was expressed in arbitrary units representing 
the ratio of the content in the fraction (%) to the sum of 
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Fig. 3. Ischemia-induced translocation of PKC-e in myocardial subfractions as shown by representative immunoblots (panel A) and quantitation of the 
blots (means + SE, n = 5) (panel B). The amounts of P1, P2 and S fractions applied were 30 ~g, 30 /zg and 20 /.~g protein, respectively. PKC-~ 
translocated from the S to the P1 fractions fraction in proportion to the time of ischemia nd to P2 fraction with a small plateau at 20 min ( * P < 0.05 vs. 
control). 
PKC-a 
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Fig. 4. In vitro proteolysis of PKC isoforms with m-calpain and antibody preadsorption with immunizing peptides. The S fraction was incubated with 
m-calpain in the presence of 1.5 mM CaC12 for 0 (lanes 1, 6) or 30 min in the absence (lanes 2, 7) or presence of 100/xM calpain inhibitor-1 (lanes 3, 8). 
For comparison, the S fractions from the control heart (lanes 4, 9) and heart rendered ischemic for 20 min (lanes 5, 10) are shown. The immunoblots were 
stained with anti-PKC isoform antibodies (lanes 1-5) or with antibodies preadsorbed with immunizing peptides (lanes 6-10). Lanes 8-10 of the blots of 
PKC-a and PKC-~ are not shown because there is no immunoreactive band. 
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Fig. 5. Immunohistochemical localization of PKC-o~ (panels A, B), PKC-6 (panels C, D), and PKC-e (panels E, F) in control heart (panels A, C, E) and 
heart after 20 min of ischemia (panels B, D, F). Sections were fixed in acetone-methanol. PKC-a lies at the intercalated discs (indicated by arrows), 
sarcolemma, nd nuclei (panels A, B). PKC-6 resides in the cell circumference and appears to decrease after the iscbemia in contrast to the strong staining 
in blood vessels (indicated by 'v') (panel D vs. C). PKC-E localizes at the nuclei (panel E, F). Longitudinal sections are shown for PKC-a and -e, while 
cross sections are shown for PKC-6 to show a clearer image. Bar = 10 /~m. 
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the means of the isoform content in the three fractions of 
control hearts (panels B). Note that the band intensities can 
be compared only within the same fractions because the 
ratios of the protein applied to the total protein varied with 
the fraction. 
PKCs-a and e were located predominantly in the 
cytosolic fraction (a ,  89.5%; e, 96.4%) (Figs. 1 and 3), 
while about half (54.2%) of PKC-6 was found in the P2 
fraction (Fig. 2). Fig. 1 shows representative immunoblots 
of the time-dependent change in PKC-a in the subcellular 
fractions during ischemia long with the quantitative data. 
PKC-a translocated from the cytosolic (S) to nuclear- 
myofibril (P1) and membrane (P2) fractions, peaking at 20 
and 10 min of ischemia, respectively. A small amount of 
50 kDa polypeptide was found in the S fraction after 
10-20 min of ischemia. Preadsorption of the antibody with 
immunizing peptide eliminated the 50 kDa and 80 kDa 
bands (Fig. 4), showing that the 50 kDa bands represents a 
proteolytic product of the 80 kDa molecule of PKC-a. 
Incubation of the S fraction from control heart with par- 
tially purified m-calpain in the presence of Ca 2 + generated 
the 50K-band while calpain inhibitor-1 suppressed the 
change (Fig. 4). The latter observation suggests that the 50 
kDa is produced by calpain, which we previously reported 
to be activated uring ischemia [28]. The total amount of 
PKC-a in the three fractions was reduced after the is- 
chemia for 40 min (85.6% of control), suggesting its 
degradation. As shown in Fig. 2, PKC-8 translocated from 
the P2 to the S fraction in proportion to the time of 
ischemia. Fig. 3 shows that PKC-e redistributed from the 
S to PI fraction with the duration of ischemia nd also to 
the P2 fraction with a small plateau at 20 min. The total 
amount of PKC-e was also reduced after ischemia (77.1% 
of control). However, the bands with molecular masses 
smaller than the native PKC-e were not diminished by the 
preadsorption with immunizing peptide (Fig. 4), indicating 
that these bands represent nonspecific reactions. The im- 
munoreactive specificities of the isoform bands were con- 
firmed by observations that the electrophoretic mobilities 
of the bands were consistent with those in a previous 
report (a ,  80K, 6, 78K, e, 97 kDa) [18] and that the 
staining of the bands was diminished by preadsorption 
with immunizing peptides (Fig. 4). Our antibodies to 
PKCs-/31 and /3 II, with which we showed the presence of 
these isoforms in the pituitary cells [33], and anti-PKC-fl 
and anti-PKC-a antibodies from Gibco did not react with 
any band with the expected molecular masses when PKC 
isoforms from brain homogenate were used as a positive 
control (not shown). On the other hand, anti-PKC-~" from 
Gibco (manuscript submitted) and anti-PKC-a from Fu- 
nakoshi (not shown) recognized each isoform in heart 
samples. 
We then examined the distribution of the PKC isoforms 
by immunohistochemstry. Fig. 5 shows the staining of 
PKC-a, t~, e in the nucleus and myocyte body (cytosol). 
Staining for PKC-a in the intercalated discs, sarcolemma, 
Table 1 
PKC activity in the P1 and P2 fractions after ischemia 
Conditions P1 P2 
control ischemia control ischemia 
Ca(+)PS (+) 687_+ 179 13145:77 * 984-I-99 1618_+173 * 
Ca(-)PS(+) 684_+59 1156:i:144' 822+27 943_+76 
Specific activities of PKC in the P1 and P2 fractions were measured for 
control hearts and hearts rendered ischemic for 20 min as described in
Section 2. Activities are expressed in arbitrary units (* P < 0.05 vs. 
control). Numbers of control and ischemic rats were both five. 
and nucleus appeared increased somewhat after 20 min of 
ischemia (panels A, B). Immunostaining for PKC-6 was 
found in the circumference of the myocytes, which is 
thought o delineate the sarcolemma, nd appeared reduced 
to some extent after ischemia (panels C, D). Furthermore, 
the nuclear staining for PKC-e appeared enhanced after 
ischemia (panels E, F). The changes in immunostaining 
after ischemia were less striking than those observed by 
immunoblotting performed under denaturing conditions for 
SDS-PAGE. 
Finally, we measured PKC activity in the P1 and P2 
fractions by using a specific substrate peptide. Table 1 
shows that the balance between the Ca 2 +-dependent activ- 
ity and Ca2+-independent activity, which is thought to 
represent the activity of conventional PKC, increased in 
the P1 and P2 fractions after ischemia for 20 min. The 
Ca2+-independent activity, which is supposed to indicate 
the sum of the activities of the novel and atypical PKC 
isoforms, was high in the P1 and P2 fractions, but in- 
creased significantly only in the P1 fraction after ischemia. 
4. Discussion 
This study demonstrates the different localizations of 
PKC-a, 6, and e isoforms and their translocation during 
myocardial ischemia (5-40 min) by combined use of 
biochemical and histochemical analyses (Figs. 1-3, 5). 
PKCs-a and e translocate from the cytosolic (S) to the 
membrane (P2) and nucleus-myofibril (P1) fractions dur- 
ing ischemia (Figs. 1 and 3). The translocation of PKC-a 
precedes that of PKC-e, suggesting different roles of the 
two isoforms during the course of ischemia (Figs. 1 and 3). 
There has been controversy concerning the presence of 
PKC-a in the cardiomyocytes of adult rats [17-24]. How- 
ever, we clearly demonstrated the presence of PKC-a and 
its translocation i myocytes during ischemia by immuno- 
blotting and immunohistochemistry (Figs. 1 and 5). The 
PKC assay data showing the presence and enhancement of 
Ca2+-dependent activity in the P1 and P2 fractions after 
ischemia supports this conclusion (Table 1). Previously, 
we used the same anti-PKC-a antibody to show the pres- 
ence of PKC-a  in a pituitary cell line [33], while at least 
three independent s udies confirmed the presence of PKC-a 
in the adult rat heart by an isoform specific antibody with 
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different epitopes [20,23,34]. Studies that showed the ab- 
sence of PKC-a appeared to employ the antibody from 
Gibco [19,21,24]. Thus, controversies concerning the ex- 
pression of PKC isoforms may arise from the diverse 
specificities of peptide antibodies among species and tis- 
sues. In further support of our conclusion, Kohout et al. 
showed the expression of the mRNA for PKCs-a, 8, •, ~" 
in the cardiomyocytes of adult rats by the reverse tran- 
scriptase-polymerase chain reaction method [35]. 
PKC-S translocated from the membrane (P2) fraction to 
the cytosolic (S) fraction with time of ischemia (Figs. 2 
and 4). This finding appears to be unique but is in line 
with a report on the abundance of PKC-8 in the particulate 
fraction of non-treated rat myocardium [19] and an obser- 
vation of the reverse translocation of PKC-8 from the 
synaptosome membrane to the cytosol and simultaneous 
translocation of PKC-• to the membrane in response to 
phorbol ester [36]. The association of PKC-8 with the 
membrane fraction in the absence of stimuli has been also 
reported in fibroblasts [37,38]. In these reports, it was 
suggested that the constitutive association of PKC-8 may 
be due to a cofactor for membrane association, specific 
lipids, PKC binding proteins, or the phosphorylation of
PKC [39,40]. On the other hand, it has been reported that 
membrane-bound PKC activity dissociates to the soluble 
fraction in adrenocortical cells after ACTH treatment [41]. 
The opposite directions of translocation of PKC-8 and 
PKC-• in the P2 fraction (Figs. 2 and 3) may account for 
the results of the PKC assay showing that Ca2+-indepen - 
dent activity was high but did not increase significantly 
after ischemia (Table), although the amount of an enzyme 
did not always parallel its activity. 
There are several reports concerning the localization of 
PKC-a and ~" in nonmyocytes of the adult rat heart 
[21,22]. Although the subfractionation study does not dif- 
ferentiate between myocyte and nonmyocyte PKC, the 
immunohistochemical study confirmed the presence of 
PKC-a, S, • isoforms in myocytes (Fig. 5). We found 
staining for PKC-a in the sarcolemma nd intercalated 
discs (Fig. 5). In rat embryo fibroblasts, PKC-a resides at 
the focal contacts where the micofilamentous cytoskeleton 
associates with the plasma membrane [42], suggesting a
regulatory role of PKC-a in the membrane-cytoskeleton 
that plays a pivotal role in maintaining cellular integrity. 
On the other hand, the immunostaining for PKC-8 ap- 
peared to decrease in the cell circumference, while that for 
PKC-• in the nucleus appeared to increase (Fig. 5). Re- 
cently, Mitchell et al. reported that PKC-S and • are 
translocated to the sarcolemma nd nuclei, respectively, 
from the cytosol after two min of ischemia followed by 10 
rain of reperfusion [24]. Their results for PKC-• are simi- 
lar to ours, but the results for PKC-8 differ. They showed 
diffuse staining for PKC-8, while we showed staining in 
the myocyte circumference in control heart (Fig. 5), con- 
sistent with the immunoblotting data (Fig. 2). The reason 
for the discrepancy is not clear. 
Cycle(s) of brief ischemia and reperfusion (ischemic 
preconditioning) limits the infarct size caused by the sub- 
sequent long ischemia in dog heart [8,9]. PKC activation 
during preconditioning is thought o protect against infarc- 
tion through the PKC-mediated activation of 5'-nucleo- 
tidase [8] or ATP-dependent K÷-channels [9]. In contrast, 
the synergistic action of hypoxia and 12-O-tetra-decanoyl- 
phorbol-13-acetate has been shown to stimulate a 
Na+/H+-exchanger, which injures cultured myocytes [6]. 
It remains to be determined which PKC isoform exerts its 
effects on ischemic injury through the phosphorylation f 
membrane proteins. 
It is thought hat PKC is involved in myocardial hyper- 
trophy, a major complication of ischemic heart disease 
[9-11 ]. The latter requires the nuclear association of PKC, 
although mitogen-activated protein kinase may mediate the 
PKC action on enhanced transcription and protein synthe- 
sis, as reported in cardiomyocytes following stretching 
[11]. In fact, there are some reports of PKC translocation 
to the nuclei in various cells including myocardium 
[23,40,41]. The present study shows that ischemia induces 
the nuclear translocation of PKCs-a and e (Figs. 1, 3 and 
4). 
In conclusion, ischemia induces the different ransloca- 
tions of each PKC isoform. This finding suggests the 
functional differentiation of PKC isoforms during is- 
chemia. 
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